• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人工智能基础:在个性化癌症免疫治疗中强制实施新抗原预测基准。

Groundwork for AI: Enforcing a benchmark for neoantigen prediction in personalized cancer immunotherapy.

机构信息

Graduate Institute of International and Development Studies, Geneva, Switzerland.

出版信息

Soc Stud Sci. 2023 Oct;53(5):787-810. doi: 10.1177/03063127231192857. Epub 2023 Aug 31.

DOI:10.1177/03063127231192857
PMID:37650579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10543129/
Abstract

This article expands on recent studies of machine learning or artificial intelligence (AI) algorithms that crucially depend on benchmark datasets, often called 'ground truths.' These ground-truth datasets gather input-data and output-targets, thereby establishing what can be retrieved computationally and evaluated statistically. I explore the case of the Tumor nEoantigen SeLection Alliance (TESLA), a consortium-based ground-truthing project in personalized cancer immunotherapy, where the 'truth' of the targets-immunogenic neoantigens-to be retrieved by the would-be AI algorithms depended on a broad technoscientific network whose setting up implied important organizational and material infrastructures. The study shows that instead of grounding an undisputable 'truth', the TESLA endeavor ended up establishing a contestable reference, the biology of neoantigens and how to measure their immunogenicity having slightly evolved alongside this four-year project. However, even if this controversy played down the scope of the TESLA ground truth, it did not discredit the whole undertaking. The magnitude of the technoscientific efforts that the TESLA project set into motion and the needs it ultimately succeeded in filling for the scientific and industrial community counterbalanced its metrological uncertainties, effectively instituting its contestable representation of 'true' neoantigens within the field of personalized cancer immunotherapy (at least temporarily). More generally, this case study indicates that the enforcement of ground truths, and what it leaves out, is a necessary condition to enable AI technologies in personalized medicine.

摘要

本文扩展了最近关于机器学习或人工智能 (AI) 算法的研究,这些算法严重依赖基准数据集,通常称为“ground truths”。这些 ground-truth 数据集收集输入数据和输出目标,从而建立可以通过计算检索和通过统计评估的内容。我探讨了 Tumor nEoantigen SeLection Alliance (TESLA) 的案例,这是一个基于联盟的个性化癌症免疫治疗中的 ground-truthing 项目,其中潜在的 AI 算法要检索的“真相”——免疫原性新抗原——取决于一个广泛的技术科学网络,其建立意味着重要的组织和物质基础设施。该研究表明,TESLA 努力并没有建立一个无可争议的“真相”,而是建立了一个有争议的参考,新抗原的生物学及其免疫原性的测量方法随着这个为期四年的项目而略有发展。然而,即使这种争议降低了 TESLA 基准的范围,它也没有使整个事业失去信誉。TESLA 项目引发的技术科学努力的规模以及它最终成功满足科学界和工业界的需求,平衡了其计量不确定性,有效地在个性化癌症免疫治疗领域(至少暂时)确立了其有争议的“真实”新抗原的代表性。更普遍地说,这个案例研究表明,实施 ground truths 及其所排除的内容是使个性化医学中的人工智能技术成为必要条件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/cde36ca14a05/10.1177_03063127231192857-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/0fc0e2670afb/10.1177_03063127231192857-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/46ed17136fab/10.1177_03063127231192857-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/ad2828c68df9/10.1177_03063127231192857-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/cde36ca14a05/10.1177_03063127231192857-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/0fc0e2670afb/10.1177_03063127231192857-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/46ed17136fab/10.1177_03063127231192857-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/ad2828c68df9/10.1177_03063127231192857-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/733d/10543129/cde36ca14a05/10.1177_03063127231192857-fig4.jpg

相似文献

1
Groundwork for AI: Enforcing a benchmark for neoantigen prediction in personalized cancer immunotherapy.人工智能基础:在个性化癌症免疫治疗中强制实施新抗原预测基准。
Soc Stud Sci. 2023 Oct;53(5):787-810. doi: 10.1177/03063127231192857. Epub 2023 Aug 31.
2
Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy.人工智能与新抗原:为精准癌症免疫治疗铺平道路。
Front Immunol. 2024 May 29;15:1394003. doi: 10.3389/fimmu.2024.1394003. eCollection 2024.
3
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.机器学习方法和协调一致的数据集可提高免疫原性新抗原预测。
Immunity. 2023 Nov 14;56(11):2650-2663.e6. doi: 10.1016/j.immuni.2023.09.002. Epub 2023 Oct 9.
4
Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy.应用于新抗原识别的人工智能有助于个性化癌症免疫治疗。
Front Oncol. 2023 Jan 9;12:1054231. doi: 10.3389/fonc.2022.1054231. eCollection 2022.
5
Tumor neoantigens: Novel strategies for application of cancer immunotherapy.肿瘤新生抗原:癌症免疫治疗的新策略。
Oncol Res. 2023 Jun 27;31(4):437-448. doi: 10.32604/or.2023.029924. eCollection 2023.
6
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.新抗原鉴定策略使难治性实体瘤的个体化免疫治疗成为可能。
J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. Print 2019 May 1.
7
A proteogenomic approach to target neoantigens in solid tumors.一种针对实体瘤中的新抗原的蛋白质基因组学方法。
Expert Rev Proteomics. 2020 Nov-Dec;17(11-12):797-812. doi: 10.1080/14789450.2020.1881889.
8
Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction.人工智能在癌症免疫疗法中的应用:在新抗原识别、抗体设计和免疫治疗反应预测中的应用。
Semin Cancer Biol. 2023 Jun;91:50-69. doi: 10.1016/j.semcancer.2023.02.007. Epub 2023 Mar 3.
9
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.采用包含新型佐剂 CAF®09b 的基于肽的新生抗原疫苗(EVX-01)进行个体化治疗,用于转移性黑色素瘤患者。
Oncoimmunology. 2022 Jan 10;11(1):2023255. doi: 10.1080/2162402X.2021.2023255. eCollection 2022.
10
SIGANEO: Similarity network with GAN enhancement for immunogenic neoepitope prediction.SIGANEO:用于免疫原性新表位预测的具有生成对抗网络增强的相似性网络
Comput Struct Biotechnol J. 2023 Oct 31;21:5538-5543. doi: 10.1016/j.csbj.2023.10.050. eCollection 2023.

引用本文的文献

1
A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies.精准免疫肿瘤学的转变?通过基于新抗原的过继性细胞疗法融合癌症基因组学与免疫疗法。
Soc Stud Sci. 2025 Aug;55(4):565-590. doi: 10.1177/03063127241303720. Epub 2024 Dec 15.
2
Enabling 'AI'? The situated production of commensurabilities.使能“人工智能”?可公度性的情境生产。
Soc Stud Sci. 2023 Oct;53(5):625-634. doi: 10.1177/03063127231194591. Epub 2023 Sep 13.

本文引用的文献

1
And say the AI responded? Dancing around 'autonomy' in AI/human encounters.并说人工智能做出了回应?在人工智能/人类交互中回避“自主性”。
Soc Stud Sci. 2024 Feb;54(1):59-77. doi: 10.1177/03063127231193947. Epub 2023 Aug 31.
2
Eye for an AI: More-than-seeing, fauxtomation, and the enactment of uncertain data in digital pathology.人工智能之眼:超越所见,虚假伪造,以及数字病理学中不确定数据的呈现。
Soc Stud Sci. 2023 Oct;53(5):712-737. doi: 10.1177/03063127231167589. Epub 2023 May 8.
3
Deciphering the immunopeptidome in vivo reveals new tumour antigens.
在体破译免疫肽组学揭示新的肿瘤抗原。
Nature. 2022 Jul;607(7917):149-155. doi: 10.1038/s41586-022-04839-2. Epub 2022 Jun 15.
4
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.癌症新抗原:预测、优先级排序及验证面临的挑战与未来方向
Front Oncol. 2022 Mar 3;12:836821. doi: 10.3389/fonc.2022.836821. eCollection 2022.
5
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.低新抗原表达和差的 T 细胞启动是结直肠癌早期免疫逃逸的基础。
Nat Cancer. 2021 Oct;2(10):1071-1085. doi: 10.1038/s43018-021-00247-z. Epub 2021 Sep 30.
6
Algorithms of Oppression: How Search Engines Reinforce Racism NYU Press, 2018. 256 pp.《压迫的算法:搜索引擎如何强化种族主义》 纽约大学出版社,2018年。256页。
Science. 2021 Oct 29;374(6567):542. doi: 10.1126/science.abm5861. Epub 2021 Oct 28.
7
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.通过联合方法揭示肿瘤抗原免疫原性的关键参数可改善新抗原预测。
Cell. 2020 Oct 29;183(3):818-834.e13. doi: 10.1016/j.cell.2020.09.015. Epub 2020 Oct 9.
8
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.肿瘤新抗原特异性过继细胞治疗:让 T 细胞产品更具个性化。
Front Immunol. 2020 Jun 26;11:1215. doi: 10.3389/fimmu.2020.01215. eCollection 2020.
9
A review of cancer immunotherapy: from the past, to the present, to the future.癌症免疫疗法综述:从过去到现在,到未来。
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1.
10
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.嵌合抗原受体 T 细胞疗法:癌症研究的前沿。
Front Immunol. 2020 Mar 5;11:176. doi: 10.3389/fimmu.2020.00176. eCollection 2020.